503B FDA Inspections: Common Findings and How to Prepare

by tmourit | Mar 27, 2026 | Audits, Quality, Regulatory

Why Are 503B Pharmacies Receiving FDA Warning Letters? 503B outsourcing facilities are registered under Section 503B of the FD&C Act and are required to comply with current Good Manufacturing Practice (CGMP) regulations under 21 CFR Parts 210 and 211. Warning...

Why 503B Pharmacies Are Struggling with FDA Inspections

by tmourit | Mar 20, 2026 | Audits, Quality

Over the past several years, inspection outcomes for 503B outsourcing facilities have trended in the wrong direction. The U.S. Food and Drug Administration has issued a steady stream of Form 483 observations and Warning Letters citing serious deficiencies in sterile...

FDA Warning Letter to Pharmacy: What the Industry Should Learn

by tmourit | Mar 6, 2026 | Audits, Quality

On January 16, 2026, the U.S. Food and Drug Administration issued a Warning Letter to Boothwyn Pharmacy, LLC following a 2025 inspection of its sterile compounding operations. For organizations involved in sterile drug production — particularly compounding pharmacies,...

How Do You Implement CAPA That Actually Works (and Satisfies Auditors)?

by tmourit | Feb 27, 2026 | Audits, Quality

Corrective and Preventive Action (CAPA) is one of the most frequently cited areas in FDA inspections, ISO audits, and notified body reviews. Despite this, many organizations still struggle to implement CAPA systems that are both effective in practice and defensible to...

Can Small or Startup Life Science Companies Be Compliant Without a Full QA Team?

by tmourit | Feb 20, 2026 | Audits, Quality

For many early stage life science companies, regulatory compliance feels like a catch-22. Regulators expect robust quality systems, documented processes, and ongoing oversight—yet hiring a full in-house Quality Assurance (QA) team is often unrealistic due to cost,...

Supplier Quality 4.0: Modernizing Supplier Management Through Risk-Based Thinking and Digital Oversight

by tmourit | Feb 13, 2026 | Audits, Quality

As global supply chains grow more complex and regulatory expectations continue to tighten, supplier quality management is undergoing a fundamental shift. Traditional, checklist-driven supplier qualification models are no longer sufficient. In their place,...

What Are the Risks of Using AI in Regulated Quality Systems?

by tmourit | Feb 6, 2026 | Audits, Quality, Regulatory

Artificial intelligence is rapidly entering quality and regulatory functions across the life sciences industry. From document analysis and gap assessments to trend detection and compliance monitoring, AI offers meaningful efficiency gains. However, in regulated...

How Does AI Change the Role of QA and RA Professionals?

by tmourit | Jan 30, 2026 | Audits, Quality, Regulatory

The short answer: AI does not replace QA or RA expertise. It reshapes it. When implemented correctly, AI reduces administrative burden, increases visibility, and elevates QA and RA professionals into more strategic, decision driven roles. The Traditional QA and RA...

Navigating the 2026 QMSR: What Medical Device Manufacturers Must Do Before February 2, 2026

by tmourit | Jan 22, 2026 | Audits, Quality, Regulatory

The U.S. Food and Drug Administration (FDA) is implementing one of the most consequential quality system changes for medical device manufacturers in decades. Effective February 2, 2026, the FDA’s new Quality Management System Regulation (QMSR) replaces the long...

How Does AI Integrate With Existing QMS or eQMS Platforms?

by tmourit | Jan 9, 2026 | Audits, Quality, Regulatory

As life science organizations face increasing regulatory complexity, many are turning to artificial intelligence to strengthen quality and regulatory compliance. Yet one question consistently rises to the top: How does AI integrate with existing QMS or eQMS platforms...

« Older Entries